Study summary

Cendakimab improved symptoms, tissue and endoscopy findings

Cendakimab trial · Phase 3 · Published September 2025, NEJM Evidence

What was tested

Cendakimab, an antibody blocking IL-13, against placebo in adults and adolescents with eosinophilic esophagitis, through 48 weeks.

What they found

Cendakimab significantly improved swallowing symptoms, tissue response and endoscopic features vs placebo.

What it means

A second IL-13 pathway option, if filed and approved.

NEJM Evid, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.